We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 183 for:    lupus | Recruiting, Not yet recruiting, Available Studies

Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus. (R-PA14098)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02891213
Recruitment Status : Not yet recruiting
First Posted : September 7, 2016
Last Update Posted : September 23, 2016
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Systemic Lupus Erythematosus (SLE) is the most common systemic autoimmune disease. The clinical manifestations are severe and affect multiple target organs such as the kidney, central nervous system, skin, heart and joints. Despite the progress made in the therapeutic approach with new immunosuppressive regimens, morbi-mortality is still high. Therefore, it's important to identify new biomarkers to help clinicians to predict severity and evolution of the disease for better adaptation of treatments and try to improve the prognosis.

RAGE (Receptor for Advanced Glycation Endproducts) :

RAGE (Receptor for Advanced Glycation Endproducts) is an ubiquitous membrane receptor, involved in development of many diseases such as diabetes, chronic renal failure but also in vascular remodelling, inflammatory, infectious deseases and cancer. RAGE regulates a number of crucial cell processes like inflammation, and tissue and cellular homeostasis.

RAGE is able to bind not only the advanced glycation end products (AGEs) such as pentosidine, carboxymethyllysine (CML), methyl-glyoxal-hydroimidazolone-1 (MG- H1), but also other ligands such as HMGB1 (high mobility group box1), and S100A8/A9 proteins which have been correlated in recent studies to the activity index of SLE. The activation of RAGE leads to a cascade of intracellular signaling and activation of the transcription factor NF-ΚB . NF-ΚB enable the traduction of proinflammatory cytokines such as IL-6, IL-1α ,IFN-γ. In SLE, these cytokines involved in perpetuation of inflammation and tissue damages including lupus nephritis. Moreover, the activation of RAGE induces the expression of adhesion molecule such as sICAM -1 and sVCAM -1 wich were recently involved in SLE vasculitis.

Soluble forms of RAGE, sRAGE and esRAGE :

RAGE is a proinflammatory membrane receptor. But RAGE also exists in soluble plasma forms, esRAGE (secreted form) and sRAGE (a truncated form as cleaved by MMP9 and ADAM10 enzymes). esRAGE and sRAGE have the same ligand-binding specificity as RAGE and may function as a 'decoy receptor' by binding pro-inflammatory ligands and preventing them from accessing cell surface RAGE (Kierdorf and Fritz, 2013). Therefore, both soluble forms have an anti-inflammatory action. Several studies have shown a decrease in circulating levels of sRAGE in patients with Rheumatoid Arthritis, or Sjögren Syndrome compared with healthy controls. However, the role of RAGE in SLE remains unknown.

RAGE and Systemic Lupus Erythematosus, recent advances :

Our team (Laboratory of Nephrology, CNRS UMR 7369, URCA) showed in a study in lupus RAGE knockout mice (B6/ MRL-FAS lpr/J RAGE-/-) a strong involvement of RAGE in systemic manifestations SLE. Recently, another report showed that sRAGE has an anti-inflammatory effect on the lupus nephritis and could be a potent therapy in mice.

In humans, two studies show a correlation between the plasma level of sRAGE and lupus phenotype ( Nienhuis et al. , 2008).

Working hypothesis :

Based on the results and those of the current studies, the investigators think that RAGE axis and its soluble forms play a crucial role in the complex pathogenesis of SLE.

The investigators hypothesize that plasma levels sRAGE and esRAGE are a reflection of the activity and the development of SLE in humans. Soluble forms of RAGE and ligands may be novel biomarkers of SLE and sRAGE a potent therapeutic target.


Condition or disease
Lupus Erythematosus

  Show Detailed Description

Study Design

Study Type : Observational
Estimated Enrollment : 150 participants
Time Perspective: Retrospective
Official Title: Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.
Study Start Date : November 2016
Estimated Primary Completion Date : January 2017
Estimated Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus
U.S. FDA Resources

Groups and Cohorts

Group/Cohort
LE (Lupus Erythematosus) group
  • Samples of the LE (Lupus Erythematosus) group from a specimen collection : "Lupus BioBanque du Rhin Supérieur" (LBBR UF 9882).
  • It's a historical cohort of lupic patients which samples have been collected from many centers in France and Germany and stored in a biobank "Lupus BioBanque du Rhin Supérieur" (project : LBBR UF 9882).


Outcome Measures

Primary Outcome Measures :
  1. concentration of RAGE ligands [ Time Frame: Day 1 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Study population is the cohort of lupic patients have been included in "Lupus BioBanque du Rhin Supérieur".
Criteria

Inclusion Criteria:

  • patients have been included in the LBBR biobank
  • absence of immunomodulatory treatment,
  • preserved renal function (MDRD> 60ml/min).

Exclusion Criteria:

  • renal failure defined by MDRD clearance < 60 mL/min/m2,
  • neoplasia,
  • diabetes,
  • other autoimmune disease,
  • current immunosuppressive treatments.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02891213


Contacts
Contact: Fatouma TOURE ftoure@chu-reims.fr
Contact: Antoine GOURY gouryantoine@gmail.com

Locations
France
Chu de Reims Not yet recruiting
Reims, France, 51092
Contact: Fatouma TOURE       ftoure@chu-reims.fr   
Contact: Antoine GOURY       gouryantoine@gmail.com   
Sponsors and Collaborators
CHU de Reims
More Information

Responsible Party: CHU de Reims
ClinicalTrials.gov Identifier: NCT02891213     History of Changes
Other Study ID Numbers: PA14098
First Posted: September 7, 2016    Key Record Dates
Last Update Posted: September 23, 2016
Last Verified: September 2016

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases